According to Mark Cuban, there are concerns about the pricing structure of Eliquis, where patients, ESI, and profits are involved, suggesting that the plan approved by @CMSGov acts as a financial benefit for PBMs.

According to Mark Cuban, major PBMs (Pharmacy Benefit Managers) are significantly increasing costs, impacting companies including those in the cryptocurrency sector if they are not utilizing pass-through PBMs. This assertion was directed towards influential figures such as Elon Musk and Bill Ackman, emphasizing the potential financial implications for businesses, including those involved with Dogecoin (DOGE), if they fail to address these inflated costs. Cuban also referenced an FRC report that utilizes their markup as a benchmark for these observations.